FDA Approves BUPROPION HYDROCHLORIDE XL — Slate Run Pharmaceuticals, LLC

# FDA Approves Slate Run Pharmaceuticals' Generic Bupropion HCl XL Slate Run Pharmaceuticals, LLC has received FDA approval for its generic formulation of bupropion hydrochloride extended-release tablets, potentially opening significant market opportunities in the antidepressant segment as patent exclusivity on branded formulations continues to erode. The approval of this widely-prescribed generic antidepressant is expected to increase competitive pricing pressure in the bupropion market and provide cost-conscious patients and insurers with more affordable treatment alternatives.